Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

image
Business Standard
177 22
Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

SI Reporter  |  Mumbai 

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

RECOMMENDED FOR YOU

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.
Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 
image
Business Standard
177 22

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

Widgets Magazine

More News

STOCK WATCH

Company Price() Chg(%)
Novartis India 833.10 17.16
Redington India 120.80 11.29
Firstsour.Solu. 41.60 5.32
Neyveli Lignite 71.45 4.69
Hathway Cable 32.75 4.13
> More on BSE Gainers
Company Price() Chg(%)
Redington India 120.85 10.97
Firstsour.Solu. 41.55 5.32
Neyveli Lignite 71.55 4.84
Kwality 113.00 4.15
Essel Propack 202.75 3.95
> More on NSE Gainers
Company Price() Chg(%)
VRL Logistics 315.10 -19.99
GVK Power Infra. 4.84 -11.52
Hind.Copper 42.75 -9.33
Just Dial 640.85 -8.74
HSIL 285.10 -8.52
> More on BSE Gainers
Company Price() Chg(%)
VRL Logistics 314.75 -19.99
GVK Power Infra. 4.85 -11.01
Hind.Copper 42.75 -9.62
HSIL 284.75 -8.57
Just Dial 640.75 -8.14
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard